IMUNON Announces Withdrawal of Form S-1 Registration Statement
IMUNON (NASDAQ: IMNN), a clinical-stage company developing DNA-mediated immunotherapy in Phase 3, has announced the withdrawal of its Form S-1 Registration Statement (No. 333-286403) with the SEC. The registration statement, originally filed on April 4, 2025, was withdrawn as the company has decided not to proceed with the planned public offering at this time. The statement had not been declared effective by the SEC, and no securities were sold in connection with the offering.
IMUNON (NASDAQ: IMNN), un'azienda in fase clinica che sviluppa immunoterapia mediata da DNA in Fase 3, ha annunciato il ritiro della sua Dichiarazione di Registrazione Modulo S-1 (n. 333-286403) presso la SEC. La dichiarazione, originariamente depositata il 4 aprile 2025, è stata ritirata poiché la società ha deciso di non procedere con l'offerta pubblica pianificata in questo momento. La dichiarazione non era stata dichiarata efficace dalla SEC e non sono stati venduti titoli in relazione all'offerta.
IMUNON (NASDAQ: IMNN), una empresa en etapa clínica que desarrolla inmunoterapia mediada por ADN en Fase 3, ha anunciado la retirada de su Declaración de Registro Formulario S-1 (No. 333-286403) ante la SEC. La declaración, presentada originalmente el 4 de abril de 2025, fue retirada ya que la compañía decidió no continuar con la oferta pública planeada en este momento. La declaración no fue declarada efectiva por la SEC y no se vendieron valores relacionados con la oferta.
IMUNON (NASDAQ: IMNN), 3상 단계에서 DNA 매개 면역치료제를 개발 중인 임상 단계 기업이 SEC에 제출한 Form S-1 등록서류(번호 333-286403)를 철회했다고 발표했습니다. 이 등록서류는 2025년 4월 4일에 처음 제출되었으나, 회사가 현재 예정된 공개 모집을 진행하지 않기로 결정함에 따라 철회되었습니다. 해당 서류는 SEC에서 효력이 인정되지 않았으며, 이와 관련된 증권 판매는 이루어지지 않았습니다.
IMUNON (NASDAQ : IMNN), une société en phase clinique développant une immunothérapie médiée par l'ADN en phase 3, a annoncé le retrait de sa déclaration d'enregistrement Formulaire S-1 (n° 333-286403) auprès de la SEC. La déclaration, initialement déposée le 4 avril 2025, a été retirée car la société a décidé de ne pas poursuivre l'offre publique prévue pour le moment. La déclaration n'avait pas été déclarée effective par la SEC et aucun titre n'a été vendu dans le cadre de cette offre.
IMUNON (NASDAQ: IMNN), ein Unternehmen in der klinischen Phase, das DNA-vermittelte Immuntherapien in Phase 3 entwickelt, hat den Rückzug seiner Form S-1-Registrierungserklärung (Nr. 333-286403) bei der SEC bekannt gegeben. Die Registrierungserklärung, ursprünglich am 4. April 2025 eingereicht, wurde zurückgezogen, da das Unternehmen beschlossen hat, das geplante öffentliche Angebot derzeit nicht durchzuführen. Die Erklärung wurde von der SEC nicht für wirksam erklärt, und es wurden keine Wertpapiere im Zusammenhang mit dem Angebot verkauft.
- None.
- Company withdraws planned public offering, potentially indicating unfavorable market conditions or financing challenges
- Withdrawal may impact the company's ability to raise capital needed for Phase 3 development
LAWRENCEVILLE, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (SEC) of the Company’s Registration Statement on Form S-1 (No. 333-286403), as amended, originally filed on April 4, 2025 (Registration Statement), as the Company no longer intends to pursue a public offering under the Registration Statement at this time. The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Company's common stock or any securities, and there shall not be any offer, solicitation or sale of securities mentioned in the press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such any state or jurisdiction.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.
Contacts:
| Media | Investors |
| Jenna Urban | Peter Vozzo |
| CG Life | ICR Healthcare |
| 212-253-8881 | 443-213-0505 |
| jurban@cglife.com | peter.vozzo@icrhealthcare.com |
FAQ
Why did IMUNON (IMNN) withdraw its S-1 Registration Statement in May 2025?
What stage of development is IMUNON's (IMNN) DNA-mediated immunotherapy in?
When did IMUNON (IMNN) originally file the withdrawn S-1 Registration Statement?
Were any securities sold before IMUNON (IMNN) withdrew its S-1 Registration?
